Concurrent mutations in EGFR or ERBB2 and KRAS are not selected for and may be considered redundant in tumor cells, thus selective pressures may account for the mutual exclusivity of EGFR/ERBB2 and KRAS [36,37,38]. Here, EGFR is linked to neoplasm.